[144] ROCKET PHARMACEUTICALS, INC. SEC Filing
Rocket Pharmaceuticals shareholder Jonathan D. Schwartz has filed to sell 14,508 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Rocket Pharmaceuticals shareholder Jonathan D. Schwartz has filed to sell 14,508 shares of common stock. The planned sale, through Fidelity Brokerage Services, has an aggregate market value of $48,051.95, with an approximate sale date of February 13, 2026 on NASDAQ.
The 14,508 shares were acquired on February 11, 2026 via restricted stock vesting from the issuer as compensation. Schwartz previously sold 2,545 common shares on November 18, 2025 for gross proceeds of $7,591.22. Shares outstanding were 108,222,228 at the time referenced.
AI-generated analysis. How Rhea-AI works. Not financial advice.